NEW YORK A recent pilot study of Pfizer's PARP inhibitor talazoparib (Talzenna) suggests that it might work as a neoadjuvant treatment for women with triple negative breast cancer and BRCA germline mutations.

Pfizer is conducting its own Phase II trial, results of which are still likely more than a year away, but the pilot, conducted by researchers from MD Anderson Cancer Center, showed promising results.

Premium Access gives you: Full site access Interest-based email alerts Access to archives Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?Login Now.

*Before your trial expires, well put together a custom quote with your long-term premium options.

Go here to read the rest:
MD Anderson Breast Cancer Pilot Shows Promising Results for Neoadjuvant Use of Pfizer PARP Inhibitor - Precision Oncology News

Comments are closed.